Amneal Secures Fourth 505(b)(2) Injectable Approval Of 2024 With Bortezomib
Amneal’s Boruzu Is Also The First Ready-To-Use Subcutaneous Formulation
Executive Summary
Highlighting the company’s ongoing turn towards more complex products, Amneal has secured the fourth approval of a 505(b)(2) injectable product this year with the greenlighting of the anti-cancer agent bortezomib.